| Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (NCT05326308) | iOMEDICO AG | 2022-04-26 |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 (NCT04274738) | X4 Pharmaceuticals | 2020-04-30 |
| R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (NCT03697356) | Kosin University Gospel Hospital | 2019-03-06 |
| A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia (NCT03225716) | Dana-Farber Cancer Institute | 2017-10-20 |
| Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (NCT02981745) | Centaurus Biopharma Co., Ltd. | 2017-04-01 |
| Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing (NCT02604511) | Dana-Farber Cancer Institute | 2016-01-01 |
| Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia (NCT02439138) | Dana-Farber Cancer Institute | 2015-10-01 |
| Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (NCT02566265) | Yale University | 2015-09-01 |
| Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia (NCT02400437) | Dana-Farber Cancer Institute | 2015-04-01 |
| Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 (NCT02363439) | Idera Pharmaceuticals, Inc. | 2014-11-01 |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia (NCT02165397) | Pharmacyclics LLC. | 2014-07-07 |
| Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (NCT02371148) | Fondazione Italiana Linfomi - ETS | 2014-06-01 |
| Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (NCT02092909) | Idera Pharmaceuticals, Inc. | 2014-03-01 |
| Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia (NCT01788020) | University of Ulm | 2013-11-01 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies (NCT01744912) | TG Therapeutics, Inc. | 2012-11-21 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia (NCT01614821) | Dana-Farber Cancer Institute | 2012-05-01 |
| Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia (NCT01470196) | Dana-Farber Cancer Institute | 2011-10-01 |
| Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia (NCT01078974) | Steven P. Treon, MD, PhD | 2010-05-01 |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (NCT01125293) | Dana-Farber Cancer Institute | 2010-04-01 |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders (NCT01177527) | Dana-Farber Cancer Institute | 2009-12-30 |
| Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (NCT00976248) | Dana-Farber Cancer Institute | 2009-11-01 |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia (NCT00936611) | Dana-Farber Cancer Institute | 2009-07-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies (NCT00697346) | Millennium Pharmaceuticals, Inc. | 2008-07-11 |
| A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma (NCT00718419) | Eli Lilly and Company | 2008-07-01 |
| Simvastatin in Waldenstrom's Macroglobulinemia (NCT00575965) | Dana-Farber Cancer Institute | 2007-11-01 |
| Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies (NCT00481871) | Acrotech Biopharma Inc. | 2007-05-01 |
| Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia (NCT01046006) | Meletios A. Dimopoulos | 2007-03-01 |
| A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia (NCT00398710) | AEterna Zentaris | 2006-10-01 |
| Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (NCT00422656) | Dana-Farber Cancer Institute | 2006-09-01 |
| Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) (NCT00422799) | Dana-Farber Cancer Institute | 2006-08-30 |
| Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia (NCT00492050) | M.D. Anderson Cancer Center | 2006-08-02 |
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies (NCT00273936) | Vertex Pharmaceuticals Incorporated | 2006-01-01 |
| Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia (NCT00250926) | Dana-Farber Cancer Institute | 2005-10-01 |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies (NCT00150462) | Amgen | 2005-09-01 |
| Sildenafil Citrate in Waldenstrom's Macroglobulinemia (NCT00165295) | Dana-Farber Cancer Institute | 2005-09-01 |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia (NCT00142129) | Dana-Farber Cancer Institute | 2003-12-01 |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. (NCT00919139) | SWOG Cancer Research Network | 2003-11-01 |
| Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia (NCT00142116) | Steven P. Treon, MD, PhD | 2003-05-01 |
| Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia (NCT00142181) | Dana-Farber Cancer Institute | 2003-03-01 |
| Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia (NCT00142155) | Dana-Farber Cancer Institute | 2002-01-01 |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood (NCT00146055) | University of Michigan Rogel Cancer Center | 2000-03-01 |